Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 0372 • ACR Convergence 2020
Tumor Necrosis Factor-α Receptor 2 Polymorphisms and Response to TNF Inhibitor Therapy in Patients with Psoriatic Arthritis
Sarah Rasheed¹, MacKenzie Dunlap¹, Jennifer Harvey¹, Connery Brennan¹, Yuxuan Jin², Unnikrishnan Chandrasekharan³ and M. Elaine Husni², ¹Cleveland Clinic Foundation, Cleveland, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have significantly improved the prognosis of patients with psoriatic arthritis (PsA); however, approximately 40% of patients do not achieve…
Abstract Number: 0833 • ACR Convergence 2020
Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics
Andrea De Diego Sola¹, César Antonio Egües Dubuc², Nerea Alcorta Lorenzo¹, Jesús Alejandro Valero Jaimes², Olga Maíz Alonso³, Luis Maria Lopez Dominguez¹, Esther Uriarte Isacelaya⁴, Jorge Cancio Fanlo⁵, María Asunción Aranguren Redondo⁶, María Belén Irastorza Larburu⁷ and Joaquín María Belzunegui Otano³, ¹Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Pais Vasco, Spain, ²Hospital Universitario Donostia, San Sebastián, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Universitario Donostia, San Sebastian, Spain, ⁵Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ⁶Pharmacology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁷Pharmacology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastián, Spain
Background/Purpose: The emergence of biological disease modifying drugs (bDMARD) has allowed a targeted approach to rheumatoid arthritis (RA) ("treat-to-treat" strategy). Once sustained remission is achieved,…
Abstract Number: 1354 • ACR Convergence 2020
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
Mark Siderius¹, Freke Wink¹, Anneke Spoorenberg¹ and Suzanne Arends¹, ¹University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
Abstract Number: 2028 • ACR Convergence 2020
Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK
Filip Van den Bosch¹, James Cheng-Chung Wei², Francisco Blanco³, Pamela Selema⁴, Daniela Graham⁵, Edmund Arthur⁶, Vassilis Tsekouras⁷, Bonnie Vlahos⁴, Chuanbo Zang⁴, Atul Deodhar⁸ and Peter Nash⁹, ¹Ghent University Hospital, Ghent, Belgium, ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, ⁴Pfizer, Collegeville, PA, ⁵Pfizer, Groton, PA, ⁶Pfizer, Peapack, NJ, ⁷Pfizer, Nicosia, Cyprus, ⁸Oregon Health & Science University, Portland, OR, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: RE-EMBARK was a phase 4, multicenter, open-label, 3-period study that evaluated etanercept (ETN) withdrawal and retreatment in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA)…
Abstract Number: 0406 • ACR Convergence 2020
Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients
José Luis Martín-Varillas¹, Belén Atienza-Mateo², Vanesa Calvo-Río³, Emma Beltran-Catalan⁴, Alfredo Adan⁵, Marisa Hernandez Garfella⁶, Elia Valls-Pascual⁷, Agustín Sellas-Fernández⁸, N Ortego⁹, Alejandro Fonollosa¹⁰, Olga Maiz Alonso¹¹, Ignacio Torre¹², Cruz Fernández-Espartero¹³, Vega Jovani¹⁴, Diana Peiteado¹⁵, David Díaz Valle¹⁶, Susana Romero-Yuste¹⁷, Elena Aurrecoechea¹, Miriam García-Arias¹⁸, Miguel Ángel Caracuel¹⁹, Santos Insúa²⁰, Senén González-Suárez²¹, Amalia Sánchez Andrade²², Luis Francisco Linares²³, Alfredo J García González²⁴, Raquel Almodovar²⁵, Carmen Carrasco Cubero²⁶, María Alcalde Villar²⁷, C Fernandez-Carballido²⁸, Fred A Pages²⁹, Eva Peña Sainz-Pardo²⁴, Rosalia Demetrio-Pablo³, Santos Castañeda³⁰, Miguel Ángel González-Gay³¹, José Luis Hernández³ and Ricardo Blanco³, ¹Hospital Sierrallana, Torrelavega, Spain, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Del Mar University Hospital, Barcelona, ⁵Hospital Clinic, Barcelona, Catalonia, Spain, ⁶H. Valencia, Valencia, Spain, ⁷H. Doctor Peset, Valencia, Spain, ⁸H. Vall d'Hebron, Barcelona, Spain, ⁹H. San Cecilio, Granada, Spain, ¹⁰H. de Cruces, Bilbao, Spain, ¹¹Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹²Hospital Basurto, Bilbao, Spain, ¹³H. Mostoles, Madrid, Spain, ¹⁴H. Alicante, Alicante, Spain, ¹⁵Hospital La Paz - IdiPAZ, Madrid, Spain, ¹⁶H. Clínico San Carlos, Madrid, Spain, ¹⁷H Pontevedra, Coruna, Spain, ¹⁸H. La Princesa, Madrid, ¹⁹H.U. Reina Sofía, Córdoba, Spain, ²⁰H. Santiago de Compostela, Santiago de Compostela, Spain, ²¹H. Cabueñes, Gijón, Spain, ²²H. Lucus Augusti, Lugo, Spain, ²³Hospital de la Arrixaca, Murcia, ²⁴H. 12 de Octubre, Madrid, Spain, ²⁵Fundación Alcorcón University Hospital, Madrid, ²⁶H. Mérida, Mérida, Spain, ²⁷H. Severo Ochoa, Madrid, Spain, ²⁸H San Juan, Alicante, Spain, ²⁹H. Palencia, Palencia, Spain, ³⁰Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³¹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Biologic therapy has improved prognosis of Behçet Disease (BD) uveitis. Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from…
Abstract Number: 0878 • ACR Convergence 2020
Absolute Lymphocyte Count Is Negatively Correlated with Atherosclerotic Cardiovascular Disease Risk Score and Red Cell Distribution Width in Psoriatic Arthritis and Increases with TNF-Inhibitor Therapy
Angela Gupta¹, Sofi Damjanovska², Alyssa Lange³, Brigid Wilson⁴, Taissa Bej⁴, Maya Mattar⁵, David Zidar⁶ and Donald Anthony⁷, ¹(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ²(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ³Case Western Reserve University, Cleveland, ⁴Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ⁵Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ⁶Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁷Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Absolute lymphocyte count (ALC) is a parameter that represents the number of lymphocytes (B, T, and NK cells) in the blood, and lymphopenia often…
Abstract Number: 1357 • ACR Convergence 2020
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
Adela Castro¹, Jesus Diaz², Guillermo Quiceno³ and John Cush⁴, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX, ⁴University of Texas Southwestern Medical School, Dallas, TX
Background/Purpose: Active ankylosing spondylitis (AS) has been associated with poor quality of life and work disability in up to 50% of patients (1). There is…
Abstract Number: 0572 • ACR Convergence 2020
Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial
Elise van Mulligen¹, Angelique Weel², Mieke Hazes³, Annette van der Helm - van Mil⁴ and Pascal de Jong¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: The benefits of tapering are a decreased risk of long-term adverse events and a reduction of health care costs, especially when bDMARDs are tapered.…
Abstract Number: 0881 • ACR Convergence 2020
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study
Irene van der Horst-Bruinsma¹, Rianne van Bentum¹, Frank Verbraak², Thomas Rath³, James Rosenbaum⁴, Bengt Hoepken⁵, Oscar Irvin-Sellers⁶, Thomas Kumke⁵, Lars Bauer⁵ and Martin Rudwaleit⁷, ¹Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ²Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³St Franziskus-Hospital, Münster, Germany, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1…
Abstract Number: 1358 • ACR Convergence 2020
Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Atul Deodhar¹, Lianne Gensler², Stephen Hall³, Philip Robinson⁴, Bengt Hoepken⁵, Lars Bauer⁵, Thomas Kumke⁵ and Walter Maksymowych⁶, ¹Oregon Health & Science University, Portland, OR, ²University of California San Francisco, San Francisco, CA, ³Cabrini Medical Centre, Monash University and Emeritus Research, Malvern, Victoria, Australia, ⁴University of Queensland, Herston, Queensland, Australia, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: This post-hoc analysis from the phase 3 C-axSpAnd study aimed to evaluate whether the response to certolizumab pegol (CZP) in non-radiographic axial spondyloarthritis (nr-axSpA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].